Skip to main content

Table 1 Characteristics of epithelioid hemangioendothelioma (EHE) in the liver, lungs, soft tissues, and bone (common presentations)

From: Epithelioid hemangioendothelioma of the thyroid: a case report

Site [ref] Sex Multicentric Metastasis Management Survival rate (5 years) Prognostic factors Treatment
Rate (%) Site
M < F 87% 36.6 Lungs, peritoneum, lymph nodes, bone Transplantation, resection, medication, radiotherapy, embolization 41 Extrahepatic disease, vascular invasion Chemotherapy (doxorubicin, cisplatin, 5FU), targeted therapy (sorafenib, pazopanib), IFN α-2b, thalidomide, lenalidomide
[1, 2023]
M < F 91% 50.5 Liver, pleura, lymph nodes Lung resection, medication 60 Hemoptysis, pleural effusion, anemia, thoracic symptoms Chemotherapy (carboplatin, paclitaxel), targeted therapy (bevacizumab, pazopanib), IFN α-2b, thalidomide, lenalidomide
Soft tissue
[10, 24]
M < F 4% 22 Lungs, lymph nodes, liver, bone Surgical resection, chemotherapy, radiotherapy 81 Mitotic activity, size ND
M > F >50% ND Uncommon Wide surgical resection, limited surgery, radiofrequency ablation, radiotherapy 92 (10 years) Visceral involvement  
  1. M male, F female, 5FU 5-fluorouracil, IFN interferon, ND not determined